MESOTHELIOMA DIAGNOSIS TEST MARKETED NATIONALLY
Commercial launch of
mesothelioma diagnosis test may make it easier for doctors to recognize and
treat mesothelioma cancer
Test products to help doctors with the diagnosis of asbestos-caused
“We believe that these highly tissue-specific tests provide more objective
and quantitative results than current methods, which may lead to more
personalized treatments for patients,” said Joseph M. Limber, president and
chief executive officer of Prometheus Laboratories.
November 2, 2009 - Prometheus Laboratories, Inc,. has announced the
nationwide commercial launch of the diagnostic test “ProOnc Mesothelioma Dx,”
which could lead to more effective treatments for patients who have received a
mesothelioma diagnosis. The
company released two other diagnostic products, as well.
The three tests Prometheus acquired rights to were initially labeled miRview™
meso, miRview™ mets and miRview™ squamous.
Now they are called ProOnc Mesothelioma Dx, ProOnc TumorSource Dx and ProOnc
Patients testing positive can apply for financial compensation through
a mesothelioma diagnosis
lawsuit. (Please see Weitz & Luxenberg questionnaire on the left.)
Mesothelioma diagnosis test
The severe latency period associated with mesothelioma (sometimes up to 50 years) can
provide a significant challenge for mesothelioma doctors trying to diagnose
patients. The similarity of mesothelioma symptoms to other, less serious
conditions also contributes to the difficulty of diagnosing patients.
The test ProOnc Mesothelioma Dx uses biomarkers in microRNAs to distinguish
the presence of mesothelioma from other cancers of the lung tissue. This test
may make it easier for doctors to obtain an accurate diagnosis for patients.
“The sensitivity and specificity of microRNA-based diagnostics should enable
clinicians to differentiate particular cancer tissues with increased confidence,
which may ultimately guide medical oncologists to deliver the safest and most
efficacious therapy for their patients,” said Harvey Pass, M.D., professor of
cardiothoracic surgery and director of the division of thoracic surgery and
thoracic oncology at New York University Langone Medical Center.
Prometheus Laboratories originally received United States rights to the three
cancer tests from Rosetta Genomics in April, 2009.
Seek compensation for asbestos-related injury
Weitz & Luxenberg has protected the legal rights of asbestos-injured
workers since 1986. And in that time the firm's mesothelioma lawyers have won
several billion dollars in verdicts and
settlements for clients injured by occupational exposure to asbestos.
If you have been diagnosed with mesothelioma and seek a free case review,
please notify us through the communication form on this page. We will pursue
your claim with vigilance to help you pay for medical bills, lost wages, and
Please know, the firm works on a contingency basis so there is no cost to you
until we obtain a verdict or reach a settlement in your favor.